Description  Claims  Drawing  Cited references 

US2009203884A   [0020] 
WO2006001023A   [0021] 
US5602095A   [0072] 

A simple and effective strategy for solving the problem of inclusion bodies in recombinant protein technology: His-tag deletions enhance soluble expression   [0002] 
Protein aggregation as bacterial inclusion bodies is reversible   [0002] 
Solubilization and refolding of bacterial inclusion body proteins   [0002]  [0002]  [0017] 
Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies   [0002]  [0002] 
Active protein aggregates produced in Escherichia coli   [0002] 
Protein quality in bacterial inclusion bodies   [0002] 
Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli   [0002] 
Use of anionic denaturing detergents to purify insoluble proteins after overexpression   [0002] 
Non-denaturing solubilization of inclusion bodies   [0002] 
Improved homogenization of recombinant Escherichia coli following pretreatment with guanidine hydrochloride   [0002] 
Purifying natively folded proteins from inclusion bodies using sarkosyl, Triton™ X-100, and CHAPS   [0002] 
Refolding and purification of recombinant L-asparaginase from inclusion bodies of E. coli into active tetrameric protein   [0002] 
Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa   [0003] 
Recombinant Expression and Purification of Pseudomonas aeruginosa Truncated Exotoxin A in Escherichia coli   [0004] 
Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner   [0005] 
Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol   [0006] 
Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication   [0007] 
In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma   [0008] 
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors   [0009] 
Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice   [0010] 
A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro   [0011] 
In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model   [0012] 
Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells   [0012] 
The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells   [0013] 
Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv   [0014] 
A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains   [0015] 
Refolding, structural transition and spermatozoa-binding of recombinant bonnet monkey (Macaca radiata) zona pellucida glycoprotein-C expressed in Escherichia coli   [0018] 
A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer   [0019] 
Pseudomonas exotoxin A: from virulence factor to anti-cancer agent   [0019] 
Advances in anticancer immunotoxin therapy   [0019] 
In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide   [0019] 
Expression, purification and characterization of an immunotoxin containing a humanized anti-CD25 single chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A   [0021] 
Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process   [0022] 
A catalytic loop within Pseudomonas aeruginosa exotoxin A modulates its transferase activity   [0078] 
Neutral red uptake assay for the estimation of cell viability/cytotoxicity   [0119]